J. Reginster

Dual energy X-ray absorptiometry-based assessment of male patients using standardized bone density values and a national reference database (2007)

Goemaere, S, Vanderschueren, D, Kaufman, J, Reginster, J, Boutsen, Y, Poriau, S, ...

Dual energy X-ray absorptiometry (DXA) measurements from different manufacturers provide different bone mineral density (BMD) values and derived T-scores and Z-scores. These differences result partly...

Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis (2002)

Johnell, O., Scheele, W. H., Lu, Y., Reginster, J., Need, A. G., Seeman, E.

Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis (2002)

Johnell, O., Scheele, W. H., Lu, Y., Reginster, J., Need, A. G., Seeman, E.

Background for studies on the treatment of male osteoporosis: state of the art

Kaufman, J, Johnell, O, Abadie, E, Adami, S, Audran, M, Avouac, B, ...

Male osteoporosis represents an important, although long underestimated, public health problem. Both in men and in women aging is accompanied by continuous bone loss and by an exponential increase in...

Degenerative musculoskeletal disease

Ethgen, O, Reginster, J

Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach

Richy, F, Bruyere, O, Ethgen, O, Rabenda, V, Bouvenot, G, Audran, M, ...

Methods: An exhaustive systematic search was performed. Inclusion criteria were: RCT or controlled study, duration of 5 days at least, inactive control, assessment of minor or major NSAID adverse...

Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib

Tannenbaum, H, Berenbaum, F, Reginster, J, Zacher, J, Robinson, J, Poor, G, ...

Objectives: To compare the efficacy and safety of lumiracoxib with placebo and celecoxib for osteoarthritis OA in a 13 week, multicentre, randomised, double blind study.

A naturalistic study of the determinants of health related quality of life improvement in osteoarthritic patients treated with non-specific non-steroidal anti-inflammatory drugs

Rabenda, V, Burlet, N, Ethgen, O, Raeman, F, Belaiche, J, Reginster, J

Objectives: To capture changes in the quality of life (QoL) occurring in patients with osteoarthritis (OA) during treatment with non-specific non-steroidal anti-inflammatory drugs (NSAIDs) and to...